AUTHORS
Alexey Martyanov, Postdoc Research Associate, Amir Hossein Kazemipour, PhD2, Valeriia Kaneva3, Federico Boggio, MD4, Matthew Richard Vander Ploeg, PhD5, David S. Paul, PhD6, Robert Lee, PhD7, Cheng Zhu, PhD8, Wolfgang Bergmeier, PhD9
AFFILIATIONS
1 UNC at Chapel Hill, Chapel Hil, North Carolina, United States, UNC at Chapel Hill, Chapel Hill, North Carolina, United States
2 Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States
3 UNC at Chapel Hill, Chapel Hil, North Carolina, United States, UNC at Chapel Hill, Chapel Hill, North Carolina, United States
4 University of Milan, Milan, Italy
5 UNC at Chapel Hill, Chapel Hil, North Carolina, United States, UNC at Chapel Hill, Chapel Hill, North Carolina, United States
6 UNC at Chapel Hill, Chapel Hil, North Carolina, United States, UNC at Chapel Hill, Chapel Hill, North Carolina, United States
7 UNC at Chapel Hill, Chapel Hil, North Carolina, United States, UNC at Chapel Hill, Chapel Hill, North Carolina, United States
8 Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States
9 UNC at Chapel Hill, Chapel Hil, North Carolina, United States, UNC at Chapel Hill, Chapel Hill, North Carolina, United States
ABSTRACT
Introduction: Multiple inflammatory and malignant disorders, including myeloproliferative neoplasms (MPNs), COVID-19, and diabetes, are associated with elevated circulating cytokines and growth factors such as IL-6, thrombopoietin (TPO), and TGFβ. These mediators prime platelets, enhancing their responsiveness to classical agonists despite causing little or no detectable activation on their own. As a result, platelet priming may evade routine ex vivo assessment and contribute to thrombotic risk that is not adequately addressed by current antiplatelet therapies, which target platelet activation pathways but do not directly inhibit cytokine-driven priming.
A common feature of many priming pathways is activation of phosphoinositide 3-kinase (PI3K), a signaling hub that also regulates αIIbβ3, the major platelet adhesion receptor. In resting platelets, αIIbβ3 adopts a low-affinity conformation, whereas classical agonist stimulation induces a high-affinity state capable of binding soluble fibrinogen and supporting aggregation. According to the prevailing model, PI3K is not sufficient to activate αIIbβ3 directly but instead functions as a permissive co-signal that sustains integrin activation by suppressing RASA3, a negative regulator of the Rap1-dependent αIIbβ3 activation pathway. However, recent structural and functional studies have shown that αIIbβ3 activation is not strictly binary and can proceed through intermediate conformational states with distinct adhesive properties. Whether PI3K-mediated inhibition of RASA3 is sufficient to drive αIIbβ3 into such an intermediate state, thereby creating a proadhesive platelet phenotype without overt activation, remains unknown.
Aims: We sought to determine whether PI3K-RASA3 signaling directly induces αIIbβ3 extension and platelet adhesiveness in the absence of overt platelet activation, to define the functional properties of this intermediate integrin state, and to assess its pharmacologic reversibility.
Methods: αIIbβ3 conformation was assessed by flow cytometry using a Förster resonance energy transfer (FRET) assay to detect integrin extension. Intermediate- and high-affinity αIIbβ3 states were defined as extended JON/A-negative and JON/A-positive conformations, respectively, and were validated by biomembrane force probe analysis adapted from Chen et al. (Nat Mater. 2019). Mechanistic studies used Rasa3hlb/hlb mice, platelet-specific Talin1-deficient (Talin1fl/fl PF4-Cre+) mice, and corresponding controls. Selective P2Y12 signaling was induced with ADP in the presence of the Gq inhibitor YM-254890. Cytokine-mediated priming was modeled using the TPO receptor agonist romiplostim. Platelet adhesion and thrombus formation on fibrin, fibrinogen, or captured VWF under flow were quantified using a custom-built microfluidic chamber system.
Results: Rasa3hlb/hlb platelets constitutively displayed an intermediate-affinity αIIbβ3 conformation and showed enhanced adhesion to fibrin under venous shear and to captured VWF under arterial shear. Both responses were abolished by platelet-specific Talin1 deficiency, demonstrating dependence on canonical integrin activation machinery. Because P2Y12 signaling suppresses RASA3, selective P2Y12 activation in mouse and human platelets phenocopied genetic RASA3 deficiency, inducing αIIbβ3 extension and enhanced adhesion. Biomembrane force probe analysis confirmed that P2Y12 signaling shifted human αIIbβ3 into an intermediate-affinity ligand-binding state. Priming WT platelets with the TPO-receptor agonist romiplostim produced the same conformational and proadhesive phenotype. PI3K inhibition prevented αIIbβ3 extension and intermediate-affinity state formation induced by either selective P2Y12 signaling or romiplostim, but had no effect in Rasa3hlb/hlb platelets, placing PI3K upstream of RASA3. Together, these findings identify PI3K-dependent RASA3 suppression as a novel biochemical mechanism for driving αIIbβ3 into an intermediate-affinity, proadhesive state.
Conclusion: Platelet priming is an active proadhesive state, not merely enhanced responsiveness to subsequent stimulation. PI3K-dependent suppression of RASA3 is sufficient to drive αIIbβ3 into an intermediate-affinity conformation that supports adhesion to fibrin and VWF without overt platelet activation. Notably, this primed integrin state is pharmacologically targetable, highlighting a potential therapeutic strategy to reduce thrombosis without broadly inhibiting platelet function.
DISCLOSURES
Alexey Martyanov, Postdoc Research Associate: No relevant conflicts of interest to declare.